产品
编 号：F147318
分子式：C27H23BrFNO4
分子量：524.38
分子式：C27H23BrFNO4
分子量：524.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1390654-28-0
产品详情
生物活性：
KRN2 (bromide) is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 0.1 μM.
体内研究：
KRN2 (3 mg/kg, i.p., daily for 2 weeks) effectively suppresses AIA in which innate immune cells play a predominant role.KRN2 (3 mg/kg, i.p., daily) effectively suppresses CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration.Animal Model:8-week-old C57BL/6 mice injected intradermally with 2 mg of complete Freund's adjuvant.
Dosage:3 mg/kg.
Administration:Peritoneally (i.p.) daily for 2 weeks.
Result:Effective in suppressing AIA.
Animal Model:8-week-old DBA/1Jmice immunized with bovine type II collagen.
Dosage:3 mg/kg.
Administration:Peritoneally (i.p.) daily.
Result:Effective in suppressing CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration.
体外研究：
KRN2 selectively suppresses the expression of pro-inflammatory genes, including Nos2 and Il6, without hampering high-salt-induced NFAT5 and its target gene expressions.KRN2 dose-dependently inhibits the NF-κB p65 binding to Nfat5 promoter 1 and directly blocks the interaction between NF-κB p65 and its DNA binding sequence in the upstream site (base pairs -3000 to +1) of Nfat5 exon 1.
KRN2 (bromide) is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 0.1 μM.
体内研究：
KRN2 (3 mg/kg, i.p., daily for 2 weeks) effectively suppresses AIA in which innate immune cells play a predominant role.KRN2 (3 mg/kg, i.p., daily) effectively suppresses CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration.Animal Model:8-week-old C57BL/6 mice injected intradermally with 2 mg of complete Freund's adjuvant.
Dosage:3 mg/kg.
Administration:Peritoneally (i.p.) daily for 2 weeks.
Result:Effective in suppressing AIA.
Animal Model:8-week-old DBA/1Jmice immunized with bovine type II collagen.
Dosage:3 mg/kg.
Administration:Peritoneally (i.p.) daily.
Result:Effective in suppressing CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration.
体外研究：
KRN2 selectively suppresses the expression of pro-inflammatory genes, including Nos2 and Il6, without hampering high-salt-induced NFAT5 and its target gene expressions.KRN2 dose-dependently inhibits the NF-κB p65 binding to Nfat5 promoter 1 and directly blocks the interaction between NF-κB p65 and its DNA binding sequence in the upstream site (base pairs -3000 to +1) of Nfat5 exon 1.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备